Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRC | P12931 | 3/20 | 0.48 |
| ▸ | BTK | Q06187 | 9/20 | 0.48 |
| ▸ | LCK | P06239 | 7/20 | 0.47 |
| ▸ | MAPK14 | Q16539 | 3/20 | 0.47 |
| ▸ | KDR | P35968 | 2/20 | 0.47 |
| ▸ | TEK | Q02763 | 2/20 | 0.47 |
| ▸ | ABL1 | P00519 | 1/20 | 0.47 |
| ▸ | FYN | P06241 | 1/20 | 0.47 |
| ▸ | CSF1R | P07333 | 1/20 | 0.47 |
| ▸ | LYN | P07948 | 1/20 | 0.47 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.47 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.46 |
| ▸ | JAK2 | O60674 | 1/20 | 0.46 |
| ▸ | BLK | P51451 | 2/20 | 0.46 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.45 |
| ▸ | HTR2A | P28223 | 1/20 | 0.45 |
| ▸ | HTR2C | P28335 | 1/20 | 0.45 |
| ▸ | JAK3 | P52333 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2496048 | 0.92 | BTK (0.57) | SRCBTKLCKMAPK14KDR | |
| SCHEMBL14286497 | 0.90 | BTK (0.56) | SRCBTKLCKMAPK14KDR | |
| SCHEMBL2495540 | 0.86 | BTK (0.61) | SRCBTKLCKMAPK14KDR | |
| SCHEMBL2498488 | 0.84 | LCK (0.67) | SRCBTKLCKMAPK14KDR | |
| SCHEMBL2496233 | 0.80 | MEN1 (0.49) | SRCBTKLCKMAPK14KDR | |
| SCHEMBL5997334 | 0.79 | KDR (0.48) | SRCLCKMAPK14KDRTEK | |
| SCHEMBL12212561 | 0.79 | SRC (0.46) | SRCBTKLCKMAPK14KDR | |
| SCHEMBL5998573 | 0.77 | OPRM1 (0.47) | SRCKDRABL1EPHX2 | |
| SCHEMBL2495207 | 0.76 | BTK (0.64) | SRCBTKLCKMAPK14KDR | |
| SCHEMBL2498530 | 0.75 | CSF1R (0.51) | SRCBTKLCKMAPK14KDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8030487-B2 | 2-amino—5-substituted pyrimidine inhibitors | TARGEGEN, INC. (US) | 2011-10-04 | — | — | US | disclosed |
| US-20080027070-A1 | 2-AMINO--5-SUBSTITUTED PYRIMIDINE INHIBITORS | TARGEGEN, INC. (US) | 2008-01-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080027070-A1 | 2-AMINO--5-SUBSTITUTED PYRIMIDINE INHIBITORS | KDR, FLT4, FLT1 | SRC 5/4885BTK 44/4885LCK 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.